<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823108</url>
  </required_header>
  <id_info>
    <org_study_id>12-08-23B</org_study_id>
    <nct_id>NCT00823108</nct_id>
  </id_info>
  <brief_title>Rapid Administration of Insulin in Sepsis</brief_title>
  <official_title>Rapid Administration of Insulin in Sepsis: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a glucose-insulin-potassium (GIK) solution can&#xD;
      be safely administered to patients with septic shock. GIK has been used in thousands of&#xD;
      critically ill patients in research studies with very few safety concerns. However, there is&#xD;
      a lack of data in regards to patients with septic shock. There are many reasons to believe&#xD;
      that GIK would be beneficial in sepsis, including improving heart function and decreasing&#xD;
      inflammation. This study will administer intravenous GIK for 12 hours continuously and&#xD;
      monitor 10 subjects for 24 hours. A control arm will be used and 10 patients will receive the&#xD;
      same monitoring but will not receive GIK.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute safety endpoint (explicit definitions)</measure>
    <time_frame>During infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in SOFA score, microcirculatory flow</measure>
    <time_frame>During infusion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucose-insulin-potassium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIK</intervention_name>
    <description>12 hour infusion of GIK solution</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Suspected or confirmed infection;&#xD;
&#xD;
          2. Any two of four criteria of systemic inflammatory response:&#xD;
&#xD;
               -  Temperature &gt; 100.4° or &lt; 96.8° F&#xD;
&#xD;
               -  Heart rate &gt; 90 beats/minute&#xD;
&#xD;
               -  Respiratory rate &gt; 20 breaths/min. or PaCO2 &lt; 32 mm Hg&#xD;
&#xD;
               -  WBC &gt;12,000 or &lt; 4000 cells/µL or &gt; 10% bands&#xD;
&#xD;
          3. Initiation of quantitative resuscitation protocol in the ED;&#xD;
&#xD;
          4. Requirement of high dose vasopressors (defined as a cumulative vasopressor index = 4)&#xD;
             to treat shock&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 years;&#xD;
&#xD;
          2. Pregnancy;&#xD;
&#xD;
          3. Any primary diagnosis other than sepsis;&#xD;
&#xD;
          4. Established Do Not Resuscitate status or advanced directives restricting aggressive&#xD;
             care or treating physician deems aggressive care unsuitable;&#xD;
&#xD;
          5. Known hyperkalemia (serum potassium &gt;5.5);&#xD;
&#xD;
          6. Dialysis-dependent renal failure;&#xD;
&#xD;
          7. Anticipated requirement for immediate surgery (within 24 hours);&#xD;
&#xD;
          8. Active participation in another interventional study;&#xD;
&#xD;
          9. Transferred from another hospital setting with sepsis therapy initiated;&#xD;
&#xD;
         10. Inability to obtain informed consent;&#xD;
&#xD;
         11. Cardiopulmonary resuscitation (chest compression or defibrillation) prior to&#xD;
             enrollment;&#xD;
&#xD;
         12. Active malignancy currently under treatment (chemo- or radiation therapy);&#xD;
&#xD;
         13. Known systemic allergy to insulin;&#xD;
&#xD;
         14. History of periodic paralysis associated with carbohydrate loading;&#xD;
&#xD;
         15. Receiving continuous intravenous inotropic support (including dobutamine, milrinone,&#xD;
             amrinone, and levosimendan).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan E Jones, MD</last_name>
    <role>Study Director</role>
    <affiliation>Carolinas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <last_update_submitted>May 31, 2011</last_update_submitted>
  <last_update_submitted_qc>May 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alan E. Jones, MD</name_title>
    <organization>Carolinas Medical Center</organization>
  </responsible_party>
  <keyword>GIK, septic shock, sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

